|
A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)
NCT ID : 05155332
Protocol Number : 1456-0001
Phase : 1
Location : Saint John's Cancer Institute
|
All Solid Tumors
|
Naveed Wagle, M.D.
|
|
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)
NCT ID : 05580562
Protocol Number : ONC201-108
Phase : 3
Location : Saint John's Cancer Institute
|
Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
|
HR+HER2- Breast Cancer
NCT ID : 04895761
Protocol Number : IMV P2100-SUR-S11
Phase : 1
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Parvin Peddi, M.D.
|
|
Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions
NCT ID : 05068726
Protocol Number : GE-280-401
Phase : 4
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Parvin Peddi, M.D.
|
|
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
NCT ID : 03739931
Protocol Number : mRNA-2752-P101
Phase : 1
Location : Santa Monica, Ca
|
All Solid Tumors
|
Kim Margolin, M.D.
|
|
Metastatic Castration-Resistant Prostate Cancer (Curium)
NCT ID : 05204927
Protocol Number : CURLu177PSM0001
Phase : 3
Location : Santa Monica, Ca
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Metastatic Hormone-Sensitive Prostate Cancer (Bayer)
NCT ID : 05059236
Protocol Number : 21516 (BAYER 1841788)
Phase : 2
Location : Santa Monica, Ca
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Metastatic Castration-Resistant Prostate Cancer (CAPItello-280)
NCT ID : 05348577
Protocol Number : D361EC00001 (CAPItello-280)
Phase : 3
Location : Santa Monica, Ca
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Multi-Arm Study of Magrolimab in Participants With Solid Tumors
NCT ID : 04827576
Protocol Number : GS-US-548-5918
Phase : 2
Location : Santa Monica, Ca
|
All Solid Tumors
|
Przemyslaw Twardowski, M.D.
|
|
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study
NCT ID : 03486873
Protocol Number : MK3475-587
Phase : 3
Location : Santa Monica, Ca
|
All Solid Tumors Multiple Tumors
|
Przemyslaw Twardowski, M.D.
|
|
Locally advanced or metastatic solid tumors: A Phase I Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects with Advanced Cancer
NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
|
All Solid Tumors Multiple Tumors
|
Kim Margolin, M.D.
|
|
Melanoma, Merkel Cell, Renal Cell NSCLC (iPREDICT)
NCT ID : 05013099
Protocol Number : IAB-CD8-203
Phase : 2b
Location : Santa Monica, CA
|
All Solid Tumors
|
Kim Margolin, M.D.
|
|
Metastatic Hormone Sensitive Prostate Cancer (Novartis)
NCT ID : 04720157
Protocol Number : CAAA617C12301
Phase : III
Location : Santa Monica, Ca
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT)
NCT ID : 04681677
Protocol Number : CTPR-0017 GLIOX
Phase : 2
Location : Santa Monica, Ca
|
Brain Tumors & Neuroscience
|
Naveed Wagle, M.D.
|
|
Unresectable, or metastatic (advanced) melanoma (IO Biotech).
NCT ID : 05155254
Protocol Number : IO102-IO103-013
Phase : III
Location : Santa Monica, Ca
|
Melanoma, Skin and Soft Tissue Tumors
|
Kim Margolin, M.D.
|
|
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
NCT ID : 05116202
Protocol Number : BO43328 (Morpheus)
Phase : Ib/2
Location : Santa Monica, Ca
|
Melanoma, Skin and Soft Tissue Tumors
|
Kim Margolin, M.D.
|
|
Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT.
NCT ID : 03488693
Protocol Number : CCTGMA.39
Phase : 3
Location : Santa Monica, CA
|
Breast Surgery and Oncology
|
Janie Grumley, M.D.
|
|
All Solid Metastatic or Advanced Tumors: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
NCT ID : 04246671
Protocol Number : TAEK-VAC-HerBy-001
Phase : 1
Location : Saint John's Cancer Institute
|
All Solid Tumors
|
Naveed Wagle, M.D.
|
|
(TRIDENT) Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With Radiation Therapy Temozolomide for the Treatment of Newly Diagnosed GBM (EF-32)
NCT ID : 04471844
Protocol Number : 2020-PT049
Phase : 3
Location : Disney Family Cancer Center
|
Brain Tumors & Neuroscience
|
Naveed Wagle, M.D.
|
|
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (WHO Grade IV)
NCT ID : 04762069
Protocol Number : CNS-201
Phase : 2
Location : Saint John's Cancer Institute
|
Brain Tumors & Neuroscience
|
Naveed Wagle, M.D.
|
|
Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT ID : 04851613
Protocol Number : LAE205INT3101
Phase : Phase Ib/II
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology Clinical Trials
|
Parvin Peddi, M.D.
|
|
Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT ID : 04958785
Protocol Number : GS-US-586-6144
Phase : 2
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Parvin Peddi, M.D.
|
|
THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 Residual Disease (RD), A Double-Blinded, PHASE III Randomized Trial Of T-DM1 And Placebo Compared With T-DM1 And TUCATINIB
NCT ID : 04457596
Protocol Number : A011801
Phase : Phase III
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology Clinical Trials
|
Parvin Peddi, M.D.
|
|
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases (SWOG)
NCT ID : 04647916
Protocol Number : S2007
Phase : 2
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Parvin Peddi, M.D.
|
|
A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
NCT ID : 04901806
Protocol Number : PBI-200-101
Phase : 1/2
Location : Santa Monica, CA
|
Multiple Tumors
|
Naveed Wagle, M.D.
|
|
White Button Mushroom Supplement for Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Naïve Patients
NCT ID : 04519879
Protocol Number : White Button Mushroom
Phase : 2
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
NCT ID : 04566393
Protocol Number : ULI-EAP-100
Phase : N/A
Location : Santa Monica, CA
|
Multiple Tumors
|
Naveed Wagle, M.D.
|
|
Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
NCT ID : 04617002
Protocol Number : ONC028
Phase : N/A
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
|
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)
NCT ID : 04142437
Protocol Number : ON-TRK
Phase : N/A
Location : Santa Monica, CA
|
Multiple Tumors
|
Naveed Wagle, M.D.
|
|
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
NCT ID : 04388475
Protocol Number : OKN-007
Phase : 2
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Santosh Kesari, M.D.
|
|
A Study of MPT-0118 as Monotherapy and in Combination with Pembrolizumab in Subjects With Advanced or Metastatic Refractory Solid Tumors
NCT ID : 04859777
Protocol Number : MPT-0118-101
Phase : 1/b
Location : Santa Monica, CA
|
All Solid Tumors Multiple Tumors
|
Przemyslaw Twardowski, M.D.
|
|
Evaluating the Clinical Efficacy of an Early-Stage Lung Cancer Detector
NCT ID : N/A
Protocol Number : CPC001-2017-S5P4-PSJHC
Phase : N/A
Location : Santa Monica, CA
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Robert McKenna, M.D.
|
|
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
NCT ID : N/A
Protocol Number : CBI_2019_SLNBprosp_001
Phase : N/A
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Richard Essner, M.D.
|
|
Anti-PD1 refractory/relapsed, unresectable Stage III or IV melanoma.
NCT ID : 04526899
Protocol Number : BNT111-01
Phase : 2
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Kim Margolin, M.D.
|
|
A First in Human Study To Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors (BETA-PRIME)
NCT ID : 04673942
Protocol Number : BETA PRIME
Phase : 1
Location : Santa Monica, CA
|
All Solid Tumors Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
|
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System In the Treatment of Subacute and Chronic Subdural Hematoma (EMBOLISE)
NCT ID : 04402632
Protocol Number : MDT19027ONYX
Phase : N/A
Location : Providence Little Company of Mary Medical Center: 4101 Torrance Blvd, Torrance, CA
|
Clinical Trials Stroke and Neurovascular Research Translational Neurosciences
|
Jason Tarpley, M.D. & Walavan Sivakumar, M.D.
|
|
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Rrial (1-BETTER) Examining XB2001 (anti-IL-1⍺ True Human antibody) in Combination with ONIVYDE + 5-FU/LV (+folinic acid) in Advanced Pancreatic Cancer
NCT ID : 04825288
Protocol Number : 2020-PT049
Phase : 3
Location : Disney Family Cancer Center
|
Gastrointestinal and Hepatobiliary Tumors
|
Karlton Wong, M.D.
|
|
A Randomized Phase 3, Double- Blinded Study Comparing Efficacy and Safety of Niraparib to Placebo in Participants with either HER-2 negative, BRCA- mutated, or Triple Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy
NCT ID : 04915755
Protocol Number : 213831
Phase : 3
Location : Disney Family Cancer Center
|
Breast Surgery and Oncology
|
Erwin Grussie, M.D.
|
|
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)
NCT ID : 04873362
Protocol Number : WO42633
Phase : 3
Location : Disney Family Cancer Center
|
Breast Surgery and Oncology
|
Erwin Grussie, M.D.
|
|
Unresectable, locally advanced/metastatic Renal Cell Carcinoma with clear cell component (with or without sarcomatoid features) ie, Stage IV Renal Cell Carcinoma
NCT ID : 04586231
Protocol Number : MK6482-011
Phase : 3
Location : Santa Monica
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Stage III or IV Melanoma: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A)
NCT ID : 04305041
Protocol Number : MK-3475-02A
Phase : 1/2
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Kim Margolin, M.D.
|
|
Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
NCT ID : 03822117
Protocol Number : INCB 54828-209
Phase : 2
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
